Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

213 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomized phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer (NCT03093155): Updated survival and subgroup analyses.
Roque DM, Siegel ER, Buza N, Bellone S, Huang GS, Altwerger G, Andikyan V, Clark M, Azodi M, Schwartz PE, Rao GG, Ratner E, Santin AD. Roque DM, et al. Among authors: siegel er. BJC Rep. 2024 Jun 20;2(1):43. doi: 10.1038/s44276-024-00067-5. BJC Rep. 2024. PMID: 39516558 Free PMC article.
Correction: Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer.
Roque DM, Siegel ER, Buza N, Bellone S, Silasi DA, Huang GS, Andikyan V, Clark M, Azodi M, Schwartz PE, Rao GG, Reader JC, Hui P, Tymon-Rosario JR, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Santin AD. Roque DM, et al. Among authors: siegel er. Br J Cancer. 2024 Apr;130(6):1073. doi: 10.1038/s41416-024-02628-4. Br J Cancer. 2024. PMID: 38438590 Free PMC article. No abstract available.
A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793).
Bellone S, Roque DM, Siegel ER, Buza N, Hui P, Bonazzoli E, Guglielmi A, Zammataro L, Nagarkatti N, Zaidi S, Lee J, Silasi DA, Huang GS, Andikyan V, Damast S, Clark M, Azodi M, Schwartz PE, Tymon-Rosario J, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Alexandrov LB, Iwasaki A, Kong Y, Song E, Dong W, Elvin J, Choi J, Santin AD. Bellone S, et al. Among authors: siegel er. Ann Oncol. 2021 Aug;32(8):1045-1046. doi: 10.1016/j.annonc.2021.04.013. Epub 2021 Apr 28. Ann Oncol. 2021. PMID: 33932502 Free PMC article. Clinical Trial. No abstract available.
Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer.
Cocco E, Bellone S, El-Sahwi K, Cargnelutti M, Casagrande F, Buza N, Tavassoli FA, Siegel ER, Visintin I, Ratner E, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD. Cocco E, et al. Among authors: siegel er. Br J Cancer. 2009 Jul 21;101(2):335-41. doi: 10.1038/sj.bjc.6605129. Epub 2009 Jun 16. Br J Cancer. 2009. PMID: 19536090 Free PMC article.
Mammaglobin B (SCGB2A1) is a novel tumour antigen highly differentially expressed in all major histological types of ovarian cancer: implications for ovarian cancer immunotherapy.
Bellone S, Tassi R, Betti M, English D, Cocco E, Gasparrini S, Bortolomai I, Black JD, Todeschini P, Romani C, Ravaggi A, Bignotti E, Bandiera E, Zanotti L, Pecorelli S, Ardighieri L, Falchetti M, Donzelli C, Siegel ER, Azodi M, Silasi DA, Ratner E, Schwartz PE, Rutherford TJ, Santin AD. Bellone S, et al. Among authors: siegel er. Br J Cancer. 2013 Jul 23;109(2):462-71. doi: 10.1038/bjc.2013.315. Epub 2013 Jun 27. Br J Cancer. 2013. PMID: 23807163 Free PMC article.
Long Term Follow up of Total Therapy IV: A Phase III Clinical Trial for Standard Risk Multiple Myeloma.
Al Hadidi S, Ababneh O, Schinke C, Thanendrarajan S, Bailey C, Smith RT, Panozzo S, Alapat D MD, Tricot GJ, Shaughnessy JD Jr, Zhan F, Sawyer JR, Siegel ER, Barlogie B, van Rhee F, Zangari M. Al Hadidi S, et al. Among authors: siegel er. Blood Adv. 2024 Dec 30:bloodadvances.2024014889. doi: 10.1182/bloodadvances.2024014889. Online ahead of print. Blood Adv. 2024. PMID: 39786380 No abstract available.
Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages.
Cheng Y, Sun F, Alapat DV, Wanchai V, Mery D, Siegel ER, Xu H, Johnson S, Guo W, Bailey C, Ashby C, Bauer MA, Hadidi SA, Schinke C, Thanendrarajan S, Zangari M, van Rhee F, Tricot G, Shaughnessy JD Jr, Zhan F. Cheng Y, et al. Among authors: siegel er. Blood Cancer J. 2024 Nov 6;14(1):194. doi: 10.1038/s41408-024-01172-x. Blood Cancer J. 2024. PMID: 39505839 Free PMC article.
213 results